Synthomer Reports H1 EBITDA Growth Amid Market Challenges, Advances Strategic Transformation

Steady Progress in Choppy Waters

Synthomer’s H1 2025 results reveal a business navigating stormy seas with impressive seamanship. While revenue dipped 9.8% to £925.2m amid global trade turbulence, the specialty chemicals firm squeezed out a 5.4% constant currency EBITDA increase to £77.8m. CEO Michael Willome’s “self-help” strategy-cost discipline and portfolio pruning-is proving its worth when macro winds turn foul.

The Earnings Engine: Margins Over Volume

Drill beneath the top-line decline and you’ll find robust margin expansion. Gross margins climbed 110bps versus H1 2024, extending a 400bps improvement over three years. How? Three key drivers:

• Pricing Power: Passed through tariff impacts via surcharges
• Cost Scalpel: £17m efficiency/reliability gains in H1
• Portfolio Shift: Relentless focus on higher-margin specialties

This trifecta lifted group EBITDA margin to 8.4% (from 7.3%) despite volumes sinking 7.1%. The standout? Adhesive Solutions-EBITDA surged 64.8% to £35.4m as their performance turnaround hit stride.

Division Deep Dive: A Tale of Three Businesses

Adhesive Solutions (AS): The Star Performer

AS isn’t just weathering the storm-it’s thriving. Margins exploded to 11.9% (from 7.1%) on £5m operational improvements. Their secret? Fixing the “end-to-end chain” from suppliers to logistics. The Henkel partnership for low-carbon adhesives exemplifies their innovation edge.

Health & Protection (HPPM): Mixed Fortunes

EBITDA jumped 21.5% to £16.6m, but beneath the surface: medical glove demand slumped 15.5% as customers burned through pre-tariff stockpiles. Offsetting this? Higher-margin reusable gloves and income from their US tech partnership. Clever portfolio tilting.

Coatings & Construction (CCS): The Drag

EBITDA sank 34.2% to £34.5m. Why? Energy solutions got clobbered by reduced oil/gas drilling. Silver lining? European construction showed green shoots. With new cost cuts accelerating, expect H2 improvement.

Strategic Shifts: Slimmer, Smarter, More Specialized

Willome’s transformation hits milestones:

• Portfolio Pruning: Sold William Blythe (May 2025), slashed sites to <30 (from 43 in 2022)
• Cost Surgery: New £20-25m annual cost program launched (250 roles cut)
• Innovation Bets: Bio-based nitrile latex (with Neste/PCS), US medical glove tech deals

The playbook is clear: fewer commodities, more IP-protected specialties.

Balance Sheet: Navigating Debt Headwinds

Net debt rose to £638.3m (H1 2024: £560.6m), but context matters:

• Seasonal working capital build (typical for H1)
• £430m+ liquidity pre-July bond repayment
• Covenants relaxed until 2026 (leverage now 4.8x)

Free cash flow should turn positive in H2, with capex tapering and working capital releases. Deleveraging remains priority #1.

Outlook: Cautious Confidence

Management guides to:

• Some EBITDA progress vs 2024’s £143.1m (continuing ops)
• Broadly neutral 2025 free cash flow
• £9m H2 benefit from new cost actions

The medium-term ambition? Doubling earnings. Betting against Willome’s margin-maximizing, portfolio-optimizing machine looks unwise-even in tariff-riddled markets.

The Takeaway: Grit Over Glamour

Synthomer won’t dazzle you with top-line fireworks. But in a sector where others drown in commodity quicksand, their specialty focus and cost discipline build lifeboats. The 110bps margin expansion amid demand chaos tells you everything. As trade winds keep gusting, this ship’s trimmed for turbulence.